Publication:
Reply to: Benefit of Helicobacter pylori eradication therapy in all systemic sclerosis patients regardless of clinical symptoms

Simple item page
dc.contributor.authorWai Chung Yongen_US
dc.contributor.authorSikarin Upalaen_US
dc.contributor.authorAnawin Sanguankeoen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherBaystate Franklin Medical Centeren_US
dc.date.accessioned2020-01-27T08:56:07Z
dc.date.available2020-01-27T08:56:07Z
dc.date.issued2019-07-01en_US
dc.identifier.citationClinical and experimental rheumatology. Vol.37, No.4 (2019), 153en_US
dc.identifier.issn0392856Xen_US
dc.identifier.other2-s2.0-85072930458en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/51047
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072930458&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleReply to: Benefit of Helicobacter pylori eradication therapy in all systemic sclerosis patients regardless of clinical symptomsen_US
dc.typeLetteren_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072930458&origin=inwarden_US

Files

Collections

Scopus 2019